Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company that focuses on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company's proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies or pathogenic B cells. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. The company's products under discovery-stage or preclinical development include DSG3/1-CAART for targeting pathogenic B cells in patients with mucocutaneous pemphigus vulgaris; MuSK-CAART for the treatment of patients with myasthenia gravis; and FVIII-CAART for use as an adjunctive therapy targeting a subset of patients with Hemophilia A. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone267-759-3100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings DateN/A
OptionableNot Optionable
Cabaletta Bio (NASDAQ:CABA) Frequently Asked Questions
What is Cabaletta Bio's stock symbol?
Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."
What price target have analysts set for CABA?
3 Wall Street analysts have issued 1 year target prices for Cabaletta Bio's shares. Their forecasts range from $19.00 to $25.00. On average, they anticipate Cabaletta Bio's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 112.6% from the stock's current price. View Analyst Price Targets for Cabaletta Bio.
What is the consensus analysts' recommendation for Cabaletta Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cabaletta Bio.
Has Cabaletta Bio been receiving favorable news coverage?
Media coverage about CABA stock has trended neutral on Friday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cabaletta Bio earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Cabaletta Bio.
Who are some of Cabaletta Bio's key competitors?
Some companies that are related to Cabaletta Bio include Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Precision BioSciences (DTIL), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), Vericel (VCEL), Atara Biotherapeutics (ATRA), Twist Bioscience (TWST), MeiraGTx (MGTX), Rubius Therapeutics (RUBY), DBV TECHNOLOGIE/S (DBVT) and Cortexyme (CRTX).
What other stocks do shareholders of Cabaletta Bio own?
Who are Cabaletta Bio's key executives?
Cabaletta Bio's management team includes the folowing people:
- Dr. Steven A. Nichtberger, Co-Founder, Chairman, CEO & Pres (Age 58)
- Dr. Michael C. Milone M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
- Dr. Aimee Payne M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
- Mr. Anup Marda M.B.A., Chief Financial Officer (Age 42)
- Mr. J. Brian Stalter J.D., Gen. Counsel (Age 47)
When did Cabaletta Bio IPO?
(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.
When did the company's quiet period expire?
Cabaletta Bio's quiet period expired on Wednesday, December 4th. Cabaletta Bio had issued 6,800,000 shares in its initial public offering on October 25th. The total size of the offering was $74,800,000 based on an initial share price of $11.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Cabaletta Bio?
Shares of CABA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cabaletta Bio's stock price today?
One share of CABA stock can currently be purchased for approximately $10.35.
How big of a company is Cabaletta Bio?
What is Cabaletta Bio's official website?
How can I contact Cabaletta Bio?
Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The company can be reached via phone at 267-759-3100 or via email at [email protected]
MarketBeat Community Rating for Cabaletta Bio (NASDAQ CABA)
MarketBeat's community ratings are surveys of what our community members think about Cabaletta Bio and other stocks. Vote "Outperform" if you believe CABA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CABA will underperform the S&P 500 over the long term. You may vote once every thirty days.
